ISSAQUAH, Wash.--(BUSINESS WIRE)--BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with ...

SAN FRANCISCO, CA, UNITED STATES, September 24, 2025 /EINPresswire.com/ -- RhythmScience, a leader in cardiac data management solutions, today announced it has ...

Panelists discuss how effective heart failure management requires collaborative care across multiple specialties (primary care, cardiology, endocrinology, nephrology) with advanced practice providers ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously difficult ...

A multicenter study has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death. A multicenter study led by Vanderbilt University Medical Center ...

A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a ...

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy - similar to that approved by the Food and Drug Administration (FDA) to treat inflammatory ...

Panelists discuss how β-blockers remain foundational therapy for heart failure with reduced ejection fraction (using evidence-based agents like carvedilol, metoprolol succinate, or bisoprolol) with ...